Novo Nordisk ® in the US as new prescriptions arter of 2022 TRx share 60% 49.0% US GLP-1 TRx market share Class growth >40% Total GLP-1 scripts (millions) 4 52.4% 38.7% 3 40% 35.8% 2 20% 0% Oct 2020 ulaglutide tirzepatide 10.3% 1 7.3% 6.4% 0 Oct 2022 Total monthly GLP-1 scripts onstitute all prescriptions of GLP-1 medications in the market and have the full month of September as latest available data point
Download PDF file